The effect of Single tablet of fixed dose Mitiglinide and Voglibose or Linagliptine with Insulin Degludec.

The effect of Single tablet of fixed dose Mitiglinide and Voglibose or Linagliptine with Insulin Degludec. - The effect of Single tablet of fixed dose Mitiglinide and Voglibose or Linagliptine with Insulin Degludec.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013689

Enrollment

Registered

2014-04-10

Start date

2014-04-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Interventions

Administration of single tablet of fixed dose mitiglinide (10 mg) and voglibose (0.2 mg) (three times a day) for 1-8 weeks and administration of linagliptin (5mg) (once a day) for 9-16 weeks with basa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes patients treated with insulin therapy and their HbA1c are less than 8.5%.

Exclusion criteria

Exclusion criteria: Patients with severe renal dysfunction, severe liver dysfunction, type 1diabetes, glutamic acid decarboxylase antibody positivity, malignancy, or other causes of hyperglycemia.

Design outcomes

Primary

Measure	Time frame
The Area Under the Curve of postprandial glucose levels after taking a test meal.	—

Secondary

Measure	Time frame
The Area Under the Curve of postprandial glucose levels after taking a low carbohydrate diet. HbA1c, GA, and 1,5-AG.	—

Countries

Japan

Contacts

Public ContactNoriko Ihana

National Center for Global Health and Medicine Depertment of Diabetes, Metabolism, and Endocrinology

nori_3373@yahoo.co.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026